

Code	IMP
Company name	Imexpharm Corporation
Date	08/06/2018
Subject	BOD resolution No.26 _ 03 Aug 2018

Content:

Imexpharm Corporation announced Resolution No.26 dated August 03, 2018 as follows:

1. Approving the business result in first six months of 2018:

- Total net revenue and other incomes: 520.5 billion dongs, achieved 37.2% compared the 2018 business plan, increased 2.0% YoY.
- Profit before tax: 80.1 billion dongs, achieved 42.2% compared the 2018 business plan, increased 7.4% YoY.

2. Approving the progress of two investment projects:

- Vinh Loc High-Tech Antibiotic Factory issued the WHO-GMP Standard Certificate in April 2018. Accordingly, the factory is preparing for EU-GMP Standard Certificate in the third quarter of 2018. Disbursement progress reached 91%
- Binh Duong High-Tech Factory finished the construction progress of 85% and disbursement progress reached 82% total investment value. Expecting the factory will finish and issues the EU-GMP Standard Certificate for late 2019 and in early 2020.

3. Approving to appoint Ms. Nguyen Thi Kim Le as Secretary of BODs, to be concurrently the person in charge of Corporate Governance.

4. Approving the report on the plan for use of 2018 Technology and Research Development Fund.

5. Approving to handle the bad debts with total value of VND1,360,597,732.

6. Approving the additional purchase of 100,000 shares of Mephydica with total investment of VND2 billion.

7. Approving to allocate 10,000 treasury shares to Mr. Nguyen Vinh Luan – Resources Development Manager.

8. Approving to expand the community house to the officers and employees in Binh Duong.